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Abstract:  Surgical resection remains the primary component of cancer therapy.  The precision required to 
successfully separate cancer tissue from normal tissue relies heavily on the surgeon’s ability to delineate 
the tumor margins.  Despite recent advances in surgical guidance and monitoring systems, intra-operative 
identification of these margins remains imprecise and directly influences patient prognosis.  If the surgeon 
had improved tools to distinguish these margins, tumor progression and unacceptable morbidity could be 
avoided.  In this article, we review the history of chlorotoxin and its tumor specificity and discuss the 
research currently being generated to target optical imaging agents to cancer tissue. 
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INTRODUCTION 
 
Cancer is the second leading cause of death in the United States with over 1.5 million people 
diagnosed each year [1].  Surgery is often the first and most important step in the long process of cancer 
treatment for patients.  The extent of tumor resection is frequently the primary indicator of whether a 
patient will suffer a relapse.  Since most tumors that recur do so at the original site of the lesion it is 
imperative that as much of the tumor is removed as possible.  However, it is often difficult for a surgeon to 
distinguish normal from neoplastic tissue, and despite the surgeons expertise tumor tissue is sometimes left 
behind.  Current technologies, such as magnetic resonance imaging (MRI), do not enable surgeons to 
directly visualize tumor margins in a real time intra-operative setting.  Research in developing tumor 
specific intra-operative imaging agents that enable surgeons to completely resect neoplastic tissue may 
have a significant impact on patient survival. 
Nowhere in the body is removing tumor tissue while sparing normal tissue more important than in 
the brain.  In the case of medulloblastoma, the most common malignant pediatric brain cancer, 80% of 
patients have a five-year survival rate when a near complete resection is achieved.  This compares to a 
50%-65% five-year survival rate if more than 1.5 cm of residual tissue remains post-surgery [2].  In the 
brain however, surgical precision is required because removing even a small amount of normal brain tissue 
could leave a patient unable to speak or walk.  It is therefore imperative that neurosurgeons have the 
capability to distinguish tumor tissue from normal healthy brain structures.  In an effort to provide surgeons 
with real-time biophotonic information to clearly define tumor margins and small foci of cancer cells, we 
recently developed a chlorotoxin-based molecular imaging probe as an effective targeting agent for many 
types of cancer.  The bioconjugate, known as “Tumor Paint” specifically binds to tumor cells without 
binding normal tissue [3].  In addition, Tumor Paint retains the ability of native chlorotoxin to cross the 
blood brain barrier, a necessary requirement for imaging brain tumors.  Tumor Paint fills the gap in current 
technology by allowing surgeons to visualize tumor tissue in a real-time intra-operative setting.  
In addition to demarcating tumor margins in the brain, surgeons also face challenges when trying 
to determine the extent of metastatic disease and lymph node infiltration in neoplasms of the prostate and 
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colon.  Tumor paint technology may provide surgical oncologists a valuable tool for real-time tumor 
detection leading to an increase in positive outcomes for patients. 
 
 
Chlorotoxin 
 
The crude venom from the scorpion Leiurus quinquestriatus was previously shown to inhibit 
reconstituted small-conductance chloride ion channels from rat epithelia and rat brain [4].  The active 
compound of this venom was purified and characterized as a small, basic, 36 amino acid peptide with 
considerable sequence homology to a class of previously described peptides of the four-disulfide core 
protein family, including the short insectotoxins, neurophysins, and agglutinins [5, 6].  Structural analysis 
by solution NMR indicates that the peptide consists of an alpha-helix linked by three disulfide bridges to a 
small, three-stranded, antiparallel beta-sheet.  The fourth disulfide bridge links the N-terminal cysteine to 
the rest of the molecule (Figure 1) [7].  The active component of the venom responsible for the inhibitory 
effect on chloride channels was named chlorotoxin [5].   
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Figure 1. Model of the three-dimensional structure of chlorotoxin with corresponding amino acid sequence 
shown below.  Disulfide bonds are shown in orange ball and stick format.  Disulfide connectivities are 
shown by solid blue lines[7]. 
 
A series of studies following the initial finding on the effects of chlorotoxin on chloride ion 
channels suggested that a glioma-specific chloride channel facilitates shape changes during glioma cell 
migration and invasion [8, 9] and that these channels are specifically targeted by chlorotoxin.  However, 
these results have been refuted [10].  First, the current was activated under non-physiological conditions 
and attempts to reproduce these experiments using the same cells under identical conditions have failed to 
confirm the original findings [10].  In addition, since verified chloride ion blockers failed to block the ion 
current, the investigators concluded that chlorotoxin blocks neither volume-regulated nor calcium-activated 
chloride channels and that they are therefore not the natural target of chlorotoxin [10]. 
 Previous studies demonstrate chlorotoxin specifically targets gliomas in which human glioma cells 
were xenografted into the cerebrum of SCID mice [11].  More recently, immunohistochemical screening of 
over 250 human biopsy samples showed selective binding of chlorotoxin to all grades of malignant gliomas 
and tumors of neuroectodermal origin, including medulloblastomas, neuroblastomas, melanomas, PNETs, 
and small cell lung carcinoma [12].  Under the same staining conditions corresponding normal tissues were 
consistently negative for chlorotoxin. 
 Due to chlorotoxin’s ability to specifically bind to malignant glioma, it is currently being 
evaluated in human clinical trials as a targeted radiotherapy agent and an imaging peptide for determining 
the extent of glioma invasion [13, 14].  In phase I clinical trials, 131I-TM-601, an 131I-labeled synthetic 
version of chlorotoxin, specifically targeted tumor tissue following an intracavitary injection [14].  131I -
TM-601 was safely administered to patients with recurrent high-grade glioma with no grade 3 or 4 
toxicities [14].  These results indicate that 131I-TM-601 can be safely administered to humans and further 
phase II clinical trials are warranted to evaluate its efficacy as a radiotherapy agent.  131I-TM-601 was also 
shown to be an effective imaging agent for evaluating tumor extent in phase I/II clinical trials and can be 
further improved with isotopes that have better imaging capabilities [13]. These studies indicate that 
 6
chlorotoxin is safe to administer in patients with brain tumors and may be an important imaging tool for 
determining the extent of neoplastic growth.  
Since chlorotoxin shows a high specificity toward gliomas and tumors of neuroectodermal origin 
[12], studies were initiated using a recombinant His6-chlorotoxin as a probe to isolate and characterize the 
true physiological target from glioma cells [15].  Contrary to the original idea that a specific chloride 
channel is the direct target of chlorotoxin, matrix metalloproteinase-2 (MMP2) was co-purified by affinity 
chromatography as part of a macromolecular complex containing MMP2, membrane type-I MMP (MT1-
MMP), v3 integrin, and tissue inhibitor of metalloprotein-2 (TIMP-2).  Further experiments demonstrated 
that chlorotoxin inhibits MMP2 enzymatic activity and causes reduction of cell surface expression of 
MMP2 and that chlorotoxin does not bind to MMP-1, MMP-3, or MMP-9 [15].  MMP2 is part of a lipid 
raft anchored protein complex that includes MT1-MMP and TIMP-2 [16, 17], and MMP2 is involved in the 
enzymatic degradation of the extracellular matrix [18, 19].  It belongs to the family of zinc dependent 
endopeptidases and is expressed in numerous tumor types [20, 21] contributing to the invasive potential of 
tumors [22].  It has been suggested that the binding of chlorotoxin to the cell surface leads to internalization 
of the entire lipid raft anchored complex containing MMP2, MT1-MMP, TIMP-2, chloride channels, and 
other proteins, thereby eliminating the functional chloride ion channel [15, 23].  Preliminary evidence using 
filipin, a cholesterol binding agent known to disrupt the caveolae endocytosis pathway, demonstrated 
decreased chlorotoxin-induced MMP2 internalization in samples treated with filipin [15, 17].  Combined, 
these data made MMP2 the leading chlorotoxin target candidate, but direct evidence of interaction between 
the proteins is lacking, as is evaluation of the other candidate targets that were co-isolated with MMP2 by 
chlorotoxin affinity chromatography.  It was recently reported that annexin A2 also acts as a target for 
TM601, a chemically synthesized, biotinylated version of chlorotoxin [24].  However, based on their 
studies, the authors also stated that membrane type metalloprotease-1 bound TM601, and additional 
proteins in macromolecular complexes may contribute to its binding.  The molecular basis of chlorotoxin’s 
specificity towards cancer is still unclear since annexin A2 is expressed intracellularly in all cells.  Further 
studies are clearly needed to conclusively identify the molecular target of chlorotoxin. 
 
Near-infrared Fluorophores  
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Fluorophores that emit in the near-infrared (NIR) range (600-900 nm) have become popular as in 
vivo imaging agents.  Since absorption of light by hemoglobin and lipids occurs below 600 nm and 
absorption of light by water occurs above 900 nm, light scattering and tissue absorption is decreased while 
tissue penetration is increased when imaging is performed within the NIR range.  In addition, tissue 
autofluoresence is high when wavelengths in the visible spectrum are used causing an increase in noise or 
background resulting in a reduction in the ability to detect specific signal from the imaging agent (Figure 
2).  These principals of NIR fluorescence in biological systems are extensively discussed in reviews by 
Ralph Weissleder and John Frangioni[25, 26]. 
 
 
Figure 2.  Autofluorescence in the brain.  Fluorescent signal in mouse brains were measured on the IVIS 
Spectrum imaging system (Caliper LifeSciences) using three excitation wavelengths (465 nm, 675 nm, 745 
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nm).  Signal was detected using the indicated emission filters.  A representative image of the brain from 
each excitation wavelength is shown and represents the expected background autofluorescence signal that 
would be produced when imaging using the wavelengths required for fluorescein (465 Ex/520 Em), Cy5.5 
(675 Ex/720 Em), and IRDye800/ICG (745 Ex/820 Em).  Each biophotonic brain image is on an identical 
pseudo-color scale in units of (p/sec/cm2/sr)/(W/cm2). 
 
 Technology that takes advantage of the naturally occurring autofluorescence inherent in 
endogenous molecules is being developed as a method of resolving tumor margins and detecting invasive 
disease in glioma tumors [27-29].  Time-resolved laser induced fluorescence spectroscopy is a technique 
that measures the unique fluorescence lifetime of endogenous biomolecules thus providing a specific 
profile for each cell type within a tissue.  This information can be converted into color images that could be 
used by a surgeon to discriminate normal from neoplastic cells.  In addition to delineating tumor margins, 
this technology may be used as a rapid intra-operative diagnostic tool for differentiating low-grade or high-
grade glioma [30]. Autofluorescent detection has also been used in colonoscopy procedures to improve 
detection of neoplasms of the colon.  In patients however, autofluorescent imaging technology failed to 
improve the detection of neoplastic lesions due to low levels of specificity [31].  While this technology is 
appealing because it does not require the use of imaging probes it remains to be determined if it is sensitive 
and specific enough to be used in a clinical setting.  
Cyanine based dyes are a broad family of fluorescent molecules.  These dyes are chemically 
synthesized fluorescent organic molecules containing an odd number of methine groups with alternating 
single and double bonds (polymethines).  The polymethine group connects two nitrogens within two 
separate aromatic moieties.  Various reactive groups such as N-hydroxysuccinamide, and maleimide can be 
attached to the side chain of the nitrogens allowing different chemistries to be utilized to react with primary 
amines and sulfhydryl groups respectively on larger macromolecules.  The chemical nature of the cyanine 
dyes and the length of the polymethine moiety can be controlled to allow fluorescence of the molecule 
within a broad range (200-900 nm) of the electromagnetic spectrum covering the ultraviolet (UV) to 
infrared (IR) range. 
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Cyanine fluorophores are bright fluorescent dyes with high molar extinction coefficients that 
generate good quantum yields.  Newer generations of these molecules have been chemically modified to be 
soluble in aqueous solutions, stable in DMSO and stable within a pH range of 3-10.  They also show 
increased photo-stability compared to earlier generations of cyanine dyes.   
Currently, only a few fluorophores are available and approved by the FDA for use in the clinic.  
Indocyanine green (ICG), [32] fluorescein-labeled serum albumin, [33] and 5-aminolevulinic acid-induced 
porphyrins [34, 35] have all been used intra-operatively to enhance tumors and delineate tumor margins 
during fluorescent guided resections of glioblastoma multiforme.  However, of these only ICG fluoresces in 
the near-infrared range and is suitable for deep tissue penetration.  Cyanine based fluorophores that emit in 
the NIR spectrum are also being developed and tested for in vivo applications.  One such dye, IRDye 
800CW, has been developed and shown to be efficacious when used for in vivo imaging applications [36, 
37].  IRDye 800CW has recently been shown to exhibit no toxic effects in an extensive toxicity study in 
rats [38].  Figure 3 shows the structure of Cy5.5 (Figure 3A) and IRDye 800CW (Figure 3B), two of the 
commercially available NIR dyes sold by Li-Cor Biosciences and GE Health Sciences respectively.  A 
summary of selected NIR dyes is shown in Figure 3C. 
 
 
 10
 
 
Figure 3.  Near-infrared dyes: (A) structure of Cy5.5 (B) structure of IRDye 800CW (C) Fluorescent 
properties of selected near-infrared dyes. 
 
Chlorotoxin-based Imaging Agents   
 
Our lab reported the development of  “Tumor Paint”, a chlorotoxin:Cy5.5 (Ctx:Cy5.5) 
bioconjugate.  Its efficacy as an in vivo imaging agent was demonstrated in mouse models of glioma, 
medulloblastoma, prostate cancer, intestinal cancer, and sarcoma [3].  We addressed the sensitivity of this 
agent for detecting cancer foci and metastasis noninvasively and under simulated surgical operating 
conditions.  The technique combines an intuitive visual guide for the surgeon with the potential for 
significant improvement in accuracy and safety.  
Preclinical development of the Ctx:Cy5.5 bioconjugate determined that the compound has 
pharmacokinetic and biodistribution properties that make it suitable for use in surgical oncology practice.  
In these studies, Ctx:Cy5.5 bound to tumor tissue as early as one day after injection and could be detected 
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in tumors as long as 14 days after injection [3].  The prolonged retention of Ctx:Cy5.5 in tumor tissue in 
mice is consistent with that observed for 131I-TM-601 in human clinical trials in patients with high grade 
glioma [13].  In these phase I/II clinical trials, free circulating 131I-TM-601 was cleared 48 hours after 
injection with tumor specific signal remaining for up to eight days after injection [13].  The extended 
retention time of Ctx:Cy5.5 in preclinical studies is promising, however, it is unknown how the conjugate 
will behave in human surgical settings.  Factors that could lead to a reduction in tumor cell specificity such 
as leakage of the probe out of the cells into surrounding normal tissue during surgery and bioconjugate 
integrity over long periods of time are to be determined.   
Biodistribution studies of chlorotoxin imaging agents indicate that chlorotoxin is cleared mainly 
by the kidney with some accumulation in the liver [3].  These studies indicate that intra-operative imaging 
in tissues other than kidney and liver, particularly in brain, prostate, and intestines where background signal 
is very low, will be beneficial in human clinical practice. 
Medulloblastoma is the most common malignant brain tumor in children.  Children diagnosed 
with medulloblastoma undergo extensive and complicated tumor resection surgery.  In some cases, it is 
difficult for a neurosurgeon to demarcate normal from diseased tissue.  The trade off of complete surgical 
resection without causing damage to normal brain has drastic consequences for the patient.  Studies have 
shown that post-operative residual disease of more than 1.5 cm results in a 50%-65% five-year survival 
rate; this compares to an 80% survival rate over the same period for standard risk patients where a complete 
resection of tumor tissue was achieved [2].  Advances in intra-operative technologies that improve the 
distinction between normal brain and tumor tissue is highly desired. 
Ctx:Cy5.5 has been extensively tested in mouse models of medulloblastoma by us [3].  Ctx:Cy5.5 
clearly demarcated tumor margins in the genetically engineered ND2:SmoA1 mouse medulloblastoma 
model.  The bioconjugate effectively labeled tumor cells in mice with bulky advanced tumors as well as 
subclinical neoplasms where only small foci of cancer cells were present (Figure 4).  These studies 
demonstrate the tumor specificity of Ctx:Cy5.5 and its ability to clearly delineate tumor cells from normal 
brain tissue [3]. 
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Figure 4.  Ctx:Cy5.5 detects tumor cells in the SmoA1 mouse medulloblastoma model. Wild type, 
asymptomatic, and symptomatic mice were injected with Ctx:Cy5.5 and then euthanized three days later.  
The brains were frozen, sliced on a cryostat, and scanned on the Odyssey infrared imaging system (LiCor 
Biosciences).  Slices were then stained with hemotoxylin and eosin (H&E).  Wild type mice (left) injected 
with Ctx:Cy5.5 show limited labeling of conjugate in normal tissue.  Mice without clinical symptoms of 
disease (middle) exhibit fluorescent signal in a small foci of cells which is shown to be tumor tissue (long 
arrow) in the cerebellum on H&E stained slides.  Ctx:Cy5.5 labeled tumor cells (long arrow) in mice with 
clinical symptoms of disease (right) while no signal is detected in the normal cerebellar structure (short 
arrow).  Signal in the fluorescent images precisely match tumor tissue visible in the H&E stained sections 
while signal in normal tissue was minimal. 
 
Ctx:Cy5.5 also targets prostate cancer [3].  The bioconjugate targeted and highlighted tumors in 
the prostate epithelium in the TRAMP mouse model of prostate cancer, where the SV40T gene is expressed 
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in the prostate epithelium [39].  In addition, small metastatic foci of cells in lymph nodes were tagged and 
detected with this molecule (Figure 5).  
Current statistics indicate that in the United States an estimated 217,730 men will develop prostate 
cancer each year [1].  Prostate cancer is the second most common cause of cancer death in men accounting 
for 29,093 deaths per year [1].  One important prognostic factor in prostate cancer survival is the detection 
and removal of cancer positive lymph nodes, which decreases a patient’s risk of tumor recurrence.  Current 
imaging technology does not accurately detect lymph node metastasis, therefore surgical dissection is the 
current state of the art in lymph node cancer detection [40].  Standard pelvic lymph node dissection 
(PLND) removes many but not all of the lymph nodes that drain from the prostate.  It has been debated if a 
more radical and extend lymphadenectomy would increase the chances of removing cancer positive lymph 
nodes therefore decreasing the likelihood of recurrence [41].  Ctx:Cy5.5 has the ability to help surgeons 
detect and resect all cancer positive lymph nodes while sparing the patient from drastic and extended 
lymphadenectomy.  Selected removal of cancer positive lymph nodes would decrease the occurrence of 
medical complications associated with both standard and extended PLND while ensuring the patient has the 
greatest survival benefit. 
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Figure 5.  Specificity of Ctx:Cy5.5 for mouse prostate cancer: (A) Biophotonic image of prostate and other 
organs from TRAMP mouse. CAP, cancerous prostate. (B) Wild-type control shows specific signal in 
TRAMP prostate and lung. Representative image from three animals in each group.  Images were obtained 
five days after injection of 0.1 mL of 10 mol/L probe. Top row, brain, heart, kidney, liver, lung, and 
spleen. Bottom row, NP, normal prostate.  (C) Intra-operative images of control (left) and TRAMP (right) 
mouse abdomen following removal of intestine, prostate, and liver.  Multiple lymph nodes (N) were 
positive by biophotonic imaging and histology. A 1.5-mm-diameter tissue nodule that was very bright on 
imaging revealed a small focus of prostate cancer cells in lymph (L) channels surrounded by fat.  Lower 
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amounts of signal were detected in fat (F) and testes (T).  (D) H&E stain showing cancer focus in lymph 
channel and cancer packed lymph node.  Figure 5 is a reproduction first published by our lab in 2005 [3]. 
 
In the United States cancers of the colon and rectum are the third leading cause of cancer related 
deaths with an estimated 72,090 new cases expected in 2010 [1].  Colonoscopy remains the most important 
colorectal cancer screening method for detecting early pre-symptomatic tumors with over 14 million 
procedures performed in the United States per year [42].  Current technology detects small precancerous 
polyps, which are surgically removed.  However, many non-cancerous polyps are often unnecessarily 
dissected increasing the risk of adverse complications for the patient [43].  Conversely, data suggests that 
26% of adenomatous polyps [44] and some distinct polyp subclasses, such as flat polyps, are often missed 
during colonoscopy [43].  In one study, flat polyps were discovered in 9.35% of patients and were 
associated with an increased incidence of carcinoma cells than the more common polyploidy lesions [45]. 
Ctx:Cy5.5 delineated intestinal cancers from normal tissue in the Apc1638N mouse model of familial 
adenomatous polyposis (FAP) [3, 46] demonstrating that chlorotoxin based imaging agents bind to 
cancerous lesions of the intestine and colon (Figure 6).  Chlorotoxin based imaging technology may 
provide a much needed tool that would help gastroenterologists identify and remove difficult to detect flat 
polyps while improving detection of neoplastic polyps and distinguishing them from non neoplastic tissue.  
 
   
 
 
Figure 6.  Ctx:Cy5.5 imaging of the Apc1638N mouse model of adenomatous polyposis (FAP) intestinal 
cancer:  (A and C) Histological confirmation of adenocarcinoma and adenoma respectively.  (B) 
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Biophotonic image of adenocarcinoma (left) and adenoma (right) shows clear delineation from normal 
intestine.  This figure is a reproduction published by our lab in 2005 [3]. 
 
  
Re-engineered and Chlorotoxin-like Peptides as Fluorescent Imaging Agents   
 
As described above, native chlorotoxin is a 36 amino acid peptide with four disulfide linkages.  
We conjugated Cy5.5 and other cyanine based NIR fluorophores to chlorotoxin using standard N-
hydroxysuccinimide ester (NHS-ester) chemistry.  Chlorotoxin has three lysines at positions 15, 23, and 27, 
and an N-terminal primary amine that can act as potential sites for conjugation.  The synthesis was 
optimized by controlling the pH, the dye to peptide molar ratio, and the reaction time, so the final 
bioconjugate would be predominantly mono-labeled [3].  However, since four sites exist that have the 
potential for conjugation, even under optimal conditions small amounts of multi-labeled product could be 
generated.  Batch to batch variations in the final composition were slight but did vary even when reaction 
conditions were identical.  A purified mono-labeled product could be obtained by reversed-phase HPLC but 
a 50% loss in final yield was not unusual and made the synthesis cost prohibitive.  Our immediate goal is to 
get US Food and Drug Administration (FDA) approval and bring the final product to clinical trial as soon 
as possible.  Delivering a final synthetic product that gives consistent and reproducible results would 
improve the chances of getting FDA approval.  In addition, a final product that has improved serum half-
life and stability would be highly desirable.  We recently reported that by substituting Lys15 and Lys23 
with either alanine or arginine in chlorotoxin eliminated the generation of multi-labeled bioconjugates 
while retaining its tumor targeting specificity [47].  We also synthesized a cyclized version of chlorotoxin 
that exhibited increased serum stability and yielded only a mono-labeled Cy5.5 product (Figure 7).  Based 
on these findings, we hope to progress these chemically re-engineered peptides as tumor imaging agents 
and advance them to human clinical trails. 
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Figure 7.  Model of the three-dimensional structure of cyclized chlorotoxin and sequences of the 
synthesized and chlorotoxin-like peptides: (A) the model of the three-dimensional structure of cyclized 
chlorotoxin showing the disulfide bonds in yellow ball and stick format, the seven amino acid linker in red 
and the lysine residues in blue. (B) amino acid sequence of native chlorotoxin (Ctx), alanine- and arginine-
substituted chlorotoxin, Buthus martensii Karsch chlorotoxin (BmKCT), and Androctonus australis 
chlorotoxin (AaCtx) [5, 47-49].   Disulfide connectivities for Ctx [7] and AaCtx [48] are show with solid 
green lines above and below the amino acid sequence respectively.  Bonds that are identical between Ctx 
and AaCtx are shown in light green and bonds that differ are indicated by dark green lines.  Note that 
disulfide connectivities for BmKCT are not available. 
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Chlorotoxin shares sequence homology and contains a number of highly conserved amino acids 
with various chlorotoxin-like peptides isolated from the venom of a number of different scorpion species 
[48, 50-57] (Figure 7).  Buthus martensii Karsch chlorotoxin (BmKCT) is a chlorotoxin-like peptide 
isolated from the venom of the Chinese scorpion indigenous to regions of China and the Korean peninsula.  
BmKCT is similar to chlorotoxin and shares 68% sequence homology with chlorotoxin isolated from 
Leiurus quinquestriatus, the Israeli death scorpion.  BmKCT is a 35 amino acid protein and, like 
chlorotoxin, contains four disulfide bridges [49].  Studies by the Li group have shown that BmKCT 
conjugated to Cy5.5 specifically targeted glioma tumors in a rat xenograft model.  In addition, both 
BmKCT and chlorotoxin inhibited glioma cell growth when expressed as a GST fusion protein [58].  
Another novel chlorotoxin-like peptide was recently purified from the venom of the scorpion Androctonus 
australis (AaCtx) and shown to have 70% amino acid sequence homology with chlorotoxin, differing by 
only twelve amino acids [48].  A synthetic version of this peptide showed weak activity on inhibiting 
glioma cell migration and invasion when compared to chlorotoxin.  The absence of negatively charged 
amino acids on the -helix and N-terminal loop may be responsible for this weak activity.  Direct 
comparison of chlorotoxin-based bioconjugates with the chlorotoxin-like peptide conjugates could 
determine which amino acids are candidates for further modification and potentially improve the binding 
characteristics, serum stability, and half-life of these tumor imaging agents. 
 
Chlorotoxin Functionalized Nanoparticles as Multi-modal Imaging Agents  
 
The use of nanoparticles in preclinical and clinical practice has recently been reviewed [59].  Non-
functionalized iron oxide nanoparticles like Feridex I.V. are currently in use in human clinical practice.  
Feridex I.V. is a widely used MRI contrast reagent consisting of superparamagnetic iron oxide particles.  
This contrast agent is not targeted and non-specifically taken up by the reticuloendothelium system of the 
liver [60].  These properties make Feridex I.V. useful as a MRI contrast enhancement agent for lesions of 
the liver but with limited utility for imaging tumors in the central nervous system.   Gadolinium-based 
contrast media are routinely used to detect tumors of the central nervous system.  The use of contrast agents 
with MRI was extensively reviewed by Marco Essig et al[61].  Gadolinium-based imaging agents are very 
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effective in delineating brain tumors but cannot cross the blood brain barrier and therefore detection is 
limited to tumors or areas within neoplastic lesions where the blood brain barrier has been disrupted.  
Alterations in the blood brain barrier are common in brain tumors but is often heterogeneous within a tumor 
and dependent on the size and shape of the lesion [61].  Contrast agents that cross the intact blood brain 
barrier and specifically bind to tumor cells have the potential to improve MRI detection and evaluation of 
central nervous system lesions.  In addition, NIR fluorescent molecules can be linked to the nanoparticle 
allowing both MRI contrast enhancement and intra-operative optical imaging capabilities. 
Chlorotoxin conjugated nanoparticles have been shown to be effective compounds for use as MRI 
contrast agents, optical imaging reagents, and carriers for DNA and chemotherapeutic agents in preclinical 
studies using mouse models of cancer.  These nano-scale materials are composed of a myriad of molecules 
(Table 1) and have varying functions and properties (Figure 8).  Since these nanoparticles are 
functionalized with a tumor targeting molecule, are small in size, and have a surface coating that enable 
them to cross the blood brain barrier, they have utility as imaging agents in tumors of the central nervous 
system.  Three distinct families of nanoparticles have been explored as chlorotoxin-functionalized particle-
based imaging agents.  Of these, iron oxide based multi-modal nanoparticles have been extensively 
developed and advanced in preclinical studies using mouse models of cancer.  In addition, two new classes 
of nanoparticles, semi-conducting polymer dots (Pdots), and rare-earth upconverting nanoparticles (UNCP) 
have recently been reported as functionalized fluorescent probes with physical properties that make them 
attractive for use as imaging agents.  
	
Table 1.  Chlorotoxin-based imaging probes. 
 
Probe Platform Imaging 
Modality 
Tumor Types Tested References 
Ctx:Cy5.5  Direct conjugate Optical 
Medulloblastoma 
Prostate Cancer 
Intestinal Cancer 
Glioma 
Rhabdomyosarcoma 
[3] 
NPCP- Iron oxide MRI Medulloblastoma [62, 63] 
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Cy5.5-Ctx PEGylated- Chitosan 
copolymer 
Optical 
NP-PEG-
Ctx and 
NP-PEG-
Cy5.5-Ctx 
Iron Oxide PEG 
coated 
MRI 
Optical 
Glioma [64, 65] 
PAMAM-
PEG-Ctx 
Polyamidoamine 
dendrimer PEG 
coated 
DNA 
delivery 
Glioma [66] 
Pdot:Ctx 
Polymer-Blend 
nanoparticle 
(PFBT/PF-DBT5) 
Optical Medulloblastoma [67] 
Ctx:UCNP 
Rare earth 
upconversion 
nanoparticles 
(NaYf4:Yb,Er/Ce) 
Optical Glioma [68] 
 
 
 
 
 
Figure 8.  General configuration of functionalized nanoparticles.  These compounds consist of a particle 
core, a polymer coating surface modification, fluorophore, and chlorotoxin for tumor targeting.  
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Iron oxide based nanoparticles that have been functionalized with chlorotoxin have been generated 
and extensively studied with the purpose of imaging brain tumors using MRI and optical imaging [63-65].  
This multi-modal approach has the added benefit of being able to take advantage of non-invasive MRI 
technology as well as fluorescent-based intra-operative technology.  These nanoparticles are composed of 
an iron oxide core coated with PEG or a combination of chitosan and PEG co-polymers (NPCP) that act as 
a scaffold for the attachment of targeting molecules and fluorescent dyes.  The polymer coating also 
functions to stabilize the particles, increase serum half-life, and prevent agglomeration.  Preclinical studies 
in mice have demonstrated the effectiveness of this multi-modal imaging approach.  Mice injected with 
chlorotoxin functionalized nanoparticles had a 38% increase in contrast enhancement in MRI scans when 
compared to non-functionalized nanoparticles in a mouse model of medulloblastoma [63].  The same 
chlorotoxin functionalized probe could be used to visualize the tumor using fluorescent-based optical 
imaging technology, showing the multi-modal capabilities of these probes [63].  Chlorotoxin functionalized 
nanoparticles have also been shown to accumulate in glioma using both MR and optical imaging [64]. 
Studies have demonstrated that chitosan/PEG co-polymer coated iron oxide nanoparticles 
functionalized with chlorotoxin exhibited favorable biodistribution profiles [62].  These nanoparticles 
distribute mainly to the liver, spleen, and kidney while having the ability to cross the blood brain barrier 
making it ideal for imaging cancers of the brain [63].  Toxicity studies in mice at a dose of 9 mg/kg 
appreciated no discernable toxic effects or lesions specifically in the liver, spleen, and kidney, the main 
clearance organs for these nanoparticles.  Studies indicate that the chlorotoxin-targeted particles circulate in 
the blood for an extended period of time, having a serum half-life of approximately eight hours in mice 
[62]. 
 Semiconducting polymer dots (Pdots) are a novel family of fluorescent probes that are of great 
interest for fluorescent-based tumor targeting applications.  Pdot probes, like quantum dots (Qdots), are 
small and extremely bright, making them appealing for use as targeted imaging probes.  Unlike quantum 
dots, Pdots are made from biologically non-toxic materials making them an attractive candidate as a 
fluorescent imaging probe for human clinical applications.  Recent advances in Pdot technology 
demonstrated targeted delivery of chlorotoxin functionalized Pdot probes [67].  These probes were on 
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average 15 nm in size, 15 times brighter than Qdots, resistant to photo-bleaching, and stable in serum for 
over seven days [67]. 
 Rare-earth metals represent a class of nanoparticle exhibiting unique properties for optical imaging 
and have recently been used for tumor targeting and imaging in live animals.  These particles absorb low 
energy NIR (930 nm) wavelengths of light and “upconvert” to emit in the red visible spectrum (660 nm).  
This allows deep tissue penetration of NIR excitation wavelengths without any autofluorescent signal 
resulting in a high signal to noise ratio.  These nanoprobes are soluble in aqueous solutions, are extremely 
photo stable, and fluoresce over long periods of time [69].  Recently, small nanoprobes (55 nm x 25 nm) of 
polyethylenimine coated hexagonal-phase NaYF4:Yb, Er/Ce nanorods were functionalized with 
chlorotoxin and used to directly visualize C6 glioma xenografted tumors in vivo [68].  The chlorotoxin 
nanoprobe effectively targeted tumor tissue after 24 hours without any appreciable signs of toxicity [68]. 
 
Challenges and Perspectives 
 
While it is clear that advances in imaging technology are needed to improve the quality of patient 
care, it remains to be seen how functionalized imaging agents will improve patient outcomes in a clinical 
setting.  Preclinical studies in mouse models indicate that these types of imaging agents may be a promising 
step in filling the gap of current imaging technology.  Optical imaging probes may provide surgeons with 
an additional tool in an integrated approach to image guided surgery where NIR fluorescently tagged 
peptides are used in combination with MRI, positron emission tomography, neuronavigation platforms, 
intra-operative MRI, and high resolution ultrasound [70].  This integrated approach is particularly 
important due to the limited depth of tissue penetration associated with fluorescent imaging and is therefore 
not suitable for deep tissue imaging. 
In addition to advances in optical imaging agents, advances in surgical instrumentation are 
required in order to bring this technology into clinical practice.  The type of intra-operative devise must be 
customized based on the surgical procedure.   Intra-operative microscopes modified with a fluorescent light 
source and detection filters have been used to detect fluorescein [71] and protoporphyrin-IX [72] 
fluorescence during resection of malignant glioma.  Additional modifications would enable surgeons to 
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detected fluorescence in the NIR range.  Fiber optic based endoscopic imaging systems have also been 
developed to detect 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX during glioma resections 
[73].  Endoscopic imaging systems could be tailored for use in open-field surgical procedures such as 
tumor margin delineation or positive lymph nodes detection or modified for use as early detection of 
intestinal lesions in a luminal space.  Neurosurgical fluorescent-based imaging is extensively discussed in a 
review by Brian W. Progue et al [74]. 
It is clear that the extent of resection has a significant impact on the progression free survival of 
patients with brain cancer.  In children with medulloblastoma, the five-year survival rate for near complete 
resection is 80% compared to a 50%-65% survival rate if significant residual post-operative tumor tissue 
remains [2].  In retrospective studies of children with malignant glioma, patients with gross total tumor 
resection survived over 60 months while patients with subtotal or limited resection survived 25 months and 
10.5 months respectively [75, 76].  The extent of surgical resection is also the most predictive prognostic 
indicator in adult cases of malignant glioma [77, 78].  These studies found that 80% of recurrences 
developed from post-operative residual tumor [77].  Studies performed by the Radiation Therapy Oncology 
Group on the 5-ALA fluorescence-guided surgery on adult patients with glioma showed an influence on the 
extent of resection on survival in some groups of patients [79].  This study also showed that patients who 
underwent surgery using 5-ALA fluorescence guided technology had a more complete tumor resection[80] 
indicating that fluorescence guided surgery can improve the quality of patient care.  The extent of tumor 
resection in not the only significant prognostic indicator and factors such as age, tumor location, and the 
degree of functional performance measured by Karnofsky Performance Status also contribute to survival 
statistics.  Additionally, even surgical resections that show no residual tumor by post-operative MRI may 
not confer a cure for patients with malignant glioma due to the infiltrative nature of the disease. 
 
CONCLUSION 
Despite advances in surgical guidance tools, clear delineation between tumor and normal tissue 
continues to rely on visual differences that are often too subtle for the neurosurgeon to differentiate.  This 
lack of visual cues often results in unacceptable morbidity and increased potential of recurrence and cancer 
progression.  As this field of research continues to advance, the discovery and synthesis of safe and novel 
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compounds with superior optical properties will allow the design of a new generation of in vivo targeted 
imaging agents for real-time surgical biophotonic imaging.  For cancers in which the extent of surgical 
resection directly correlates with patient survival, the advancement of these targeted fluorescent probes to 
human clinical trials offers an opportunity to fundamentally improve cancer survivorship. 
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